• Who We Are

     

     

     

     

     

     

  • Executive Board of Directors

    Tim Coleman, PhD – Co-founder

    President, Nemucore Medical Innovations

    Todd Crowley – Co-founder

    Managing Partner, Tower Hill Financial Group

    Amanda Crowley – Co-founder

    Teacher, Parent Advocate

    Gerry McDougall

    Partner, PricewaterhouseCoopers Health Sciences

    Walter Ogier

    Founder, Acetylon Pharmaceuticals

    Stacie Weninger, PhD

    President, Fidelity Biosciences Research Initiative (FBRI)

    Clinical Advisors

    Jennifer Frankovich, MD

    Associate Clinical Professor, Department of Pediatrics

    Division of Allergy, Immunology Rheumatology
    Stanford University/Lucile Packard Children’s Hospital

     

    Mark Pasternack, MD

    Chief, Pediatric Infectious Disease, Associate professor of Pediatrics

    Massachusetts General Hospital

     

    Kyle Williams, MD, PhD

    Director, Pediatric Neuropsychiatry and Immunology Program

    Massachusetts General Hospital
    Instructor in Psychiatry, Harvard Medical School

    Parent Committee Members

    Stacey Detrick-Lerner

    Jennifer Dolins

    Elana November, PsyD

    Blake Poggi

  • Scientific Advisory Board

    Paola Arlotta, PhD

    Chair, Harvard Department of Stem Cell and Regenerative Biology

    Professor of Stem Cell and Regenerative Biology

    Principal Faculty, Harvard Stem Cell Institute

     

    Dr. Paola Arlotta is a professor of stem cell and regenerative biology at Harvard University, and chair of Harvard Department of Stem Cell and Regenerative Biology (HSCRB). She is a principal faculty member at the Harvard Stem Cell Institute, where she is co-director of the neuroscience program, an institute member at the Broad Institute, and an associate member of the Stanley Center for Psychiatric Research at the Broad Institute. A leading neuroscientist, Dr. Arlotta is interested in understanding the molecular laws that govern the birth, differentiation, and assembly into working circuitry of clinically relevant neuron types in the cerebral cortex.

    Guoping Feng, PhD

    Professor of Neuroscience, Department of Brain and Cognitive Sciences, MIT

     

    Dr. Guoping Feng is the Poitras Professor of Neuroscience at the McGovern Institute for Brain Research in the Department of Brain and Cognitive Sciences at MIT and senior scientist at the Stanley Center for Psychiatric Research at Broad Institute, most notable for studying the synaptic mechanisms underlying psychiatric disease. In addition to developing many genetic-based imaging tools for the study of molecular mechanisms in the brain, he has generated and characterized rodent models of obsessive-compulsive disorder, autism spectrum disorders, and schizophrenia, leading to fundamental new insights into brain disorders.

    Mark Fishman, MD

    Professor of Stem Cell and Regenerative Biology, Harvard University

     

    Dr. Mark Fishman currently serves as Professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service at the MGH for patients with complex medical disorders. He was previously Chief of Cardiology at Massachusetts General Hospital, and director of the Cardiovascular Research Center at Massachusetts General Hospital. He is a fellow of the National Academy of Arts and Sciences and a member of the National Academy of Sciences, Institute of Medicine.

     

    Dr. Fishman was appointed President of the newly founded Novartis Institutes for BioMedical Research in 2002 to implement a new strategy in Novartis' global drug discovery effort. During his tenure, NIBR discovered and brought through successful clinical trials of 90 new medicines in more than 120 indications. He is the author of over 100 publications and known for pioneering research using the zebrafish as a means of visualizing the development of the circulatory system and as a model for human disease.

    Carole Ho, MD

    Chief Medical Officer and Head of Development, Denali Therapeutics

     

    Dr. Carole Ho currently serves as Chief Medical Officer and Head of Development at Denali Therapeutics in San Francisco, CA. Denali Therapeutics is dedicated to therapeutic discovery and development of treatments for neurodegenerative diseases. Previously, Dr. Ho served as Vice President of Early Clinical Development at Genentech, where she headed the early clinical development for all indications outside of oncology, including neurology, ophthalmology, immunology, and infectious disease. She served as Group Medical Director of Rheumatology and Group Medical Director of Personalized Health Care for Inflammatory diseases. Prior to Genentech, she held a faculty appointment in the Department of Neurology at Stanford University and was subsequently a Medical Director at Johnson and Johnson.

    Steven E. Hyman, MD

    Director of the Stanley Center for Psychiatric Research, Broad Institute
    Core Faculty member at the Broad Institute of Harvard and MIT

     

    Dr. Steven Hyman is currently Director of the Stanley Center for Psychiatric Research and a member at the Broad Institute of MIT and Harvard. Dr. Hyman served as Provost of Harvard University, the University’s chief academic officer from 2001 to 2011. As Provost, he had a special focus on developing collaborative initiatives in the sciences and engineering spanning multiple disciplines and institutions. From 1996 to 2001, he served as director of the US National Institute of Mental Health (NIMH). Hyman is member of the National Academy of Medicine (NAM). In the past, he has chaired the National Academies of Sciences, Engineering, and Medicine Forum on Neuroscience and Nervous System Disorders (2012-2018); served as Editor of the Annual Review of Neuroscience (2001-2016); and served as President of the Society for Neuroscience (2015).

     

    Dr. Hyman serves as a Board Vice-Chair of the Charles A. Dana Foundation and as a Director of the Charles Revson Foundation. He is a Director of two biotechnology companies, Voyager Therapeutics and Q State Biosciences and serves on multiple Scientific Advisory Boards including Janssen, BlackThorn, and F-Prime. He is a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Association for the Advancement of Science, and a Distinguished Life Fellow of the American Psychiatric Association.

    Mustafa Sahin, MD, PhD

    Director, Translational Neuroscience Center, Boston Children’s Hospital

    Professor of Neurology, Harvard Medical School

     

    Dr. Mustafa Sahin is currently the director of the Translational Neuroscience Center at Boston Children's Hospital and Rosamund Stone Zander Chair professor of neurology at Harvard Medical School. Dr. Sahin serves as an expert for the Department of Neurology for Boston Children's Hospital Precision Medicine Service. Work in his lab has identified the mechanisms by which tuberous sclerosis leads to miswiring of neurons in the brain and potential therapies for this disorder. Current research focuses on translating these preclinical findings into the clinic and developing treatments for epilepsy and autism associated with activation of the mTOR pathway. He directs two national consortia to study biomarkers and comparative pathobiology of TSC and related neurodevelopmental disorders.

    Beth Stevens, PhD

    Associate professor, Department of Neurology, Harvard Medical School

     

    Dr. Beth Stevens is a Research Associate in Neurology at Boston's Children's Hospital, Associate Professor of Neurology at Harvard Medical School, and institute member of the Broad Institute of MIT and Harvard. Stevens's work has led her to the discovery of different roles of microglia, leading to fundamental new insights into neuro/immune interactions in disease. She is a recipient of the 2008 Smith Family Award for Excellence in Biomedical Research, a 2010 Dana Foundation Award (Brain and Immunoimaging), and a 2010 Ellison Medical Foundation New Scholar in Aging award. Dr. Stevens received the Presidential Early Career Award for Scientists and Engineers in 2012. In 2015, she was selected for a MacArthur Foundation Fellowship “Genius Award.”

    Kyle Williams, MD, PhD

    Director, Pediatric Neuropsychiatry and Immunology Program, Massachusetts General Hospital

    Instructor in Psychiatry at Harvard Medical School

     

    Dr. Kyle Williams currently serves as the Director of the Pediatric Neuropsychiatry and Immunology Program in the OCD and Related Disorders Program at Massachusetts General Hospital. Dr. Williams’s primary clinical and research interests involve the intersection of the brain and the immune system, and in particular, the psychiatric and behavioral consequences of these interactions. He has published peer reviewed articles and book chapters on Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections, Obsessive Compulsive Disorder and Tourette's syndrome. He additionally serves as an instructor in Psychiatry at Harvard Medical School.

    Henrik Zetterberg, MD, PhD

    Professor of Neurochemistry, Head of Lab, University College London
    Professor of Neurochemistry, Head of Department, University of Gothenburg

     

    Dr. Henrik Zetterberg is Professor of Neurochemistry, senior consultant of clinical chemistry, and head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, where he is also co-leads the Clinical Neurochemistry Laboratory. Additionally, he leads the fluid biomarker unit at the Leonard Wolfson Experimental Neurology Centre, University College London. With a background in molecular biology and medicine, Dr. Zetterberg has spent the last 10 years developing biomarkers for Alzheimer's disease and other brain disorders.